Type 2 diabetes mellitus (T2DM) and COVID-19 are known to independently increase the risk of developing dementia. This study investigates whether the choice of antidiabetic treatment influences the risk of incident dementia in COVID-19 survivors with T2DM.
What this study does not show
This study does not establish a direct causal relationship between GLP-1 receptor agonist therapy and reduced dementia risk, nor does it provide definitive clinical recommendations.
Evidence scorecard
- Analytic validity: established
- Clinical validity: established
- Clinical utility: partial
The study utilized a target trial emulation approach, leveraging data from the TriNetX US Collaborative Network. It focused on COVID-19 survivors aged 50 years and older who initiated either GLP-1 receptor agonist (GLP-1RA) therapy or dipeptidyl peptidase-4 inhibitor (DPP-4i) therapy between January 1, 2020, and December 31, 2024.
In total, 25,263 patients were matched in each group, with follow-up durations averaging around 919 days for the GLP-1RA group and 955 days for the DPP-4i group. The primary outcome measured was incident all-cause dementia, which included vascular dementia, Alzheimer’s disease, and other forms of dementia.
The results indicated that initiation of GLP-1RA therapy was associated with a significantly lower hazard of developing incident dementia (hazard ratio [HR] of 0.64, 95% confidence interval [CI] 0.58-0.72). This trend was also observed for vascular dementia (HR 0.67, 95% CI 0.52-0.85) and Alzheimer’s disease (HR 0.74, 95% CI 0.59-0.93). Additionally, patients on GLP-1RA therapy exhibited better glycemic control and lower all-cause mortality (HR 0.63, 95% CI 0.59-0.68).
While the association with mild cognitive impairment was noted, it was borderline (HR 0.87, 95% CI 0.75-1.00) and not consistently supported across sensitivity analyses. The findings remained robust even after conducting a 6-month landmark analysis, reinforcing the association of GLP-1RA with reduced dementia risk (HR 0.66, 95% CI 0.58-0.75).
These results suggest that among COVID-19 survivors with T2DM, the initiation of GLP-1RA therapy may be linked to a lower risk of incident dementia compared to DPP-4i therapy. However, the authors emphasize that these findings are hypothesis-generating and require further investigation before being applied in clinical settings.